10-Q · May 14, 2026
Telomir Pharmaceuticals reported a net loss of approximately $990,947 for Q1 2026, a significant decrease from a loss of $2.2 million in the same quarter of 2025. The company has begun a pivotal clinical trial for its…
Earnings analysis · 10-Q
TELO earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
This 10-Q extract does not provide the income statement, balance sheet, cash flow statement, segment data, or quantitative financial outlook, so revenue, margins, EPS, cash flow, and balance-sheet trends cannot be…
Read full summary
This 10-Q extract does not provide the income statement, balance sheet, cash flow statement, segment data, or quantitative financial outlook, so revenue, margins, EPS, cash flow, and balance-sheet trends cannot be assessed from the supplied filing text. Management reported effective disclosure controls as of June 30, 2026 and no material internal-control changes during the second quarter of 2026. The principal newly disclosed negative is a legal claim seeking more than $3.5 million; management states that there were no material changes to the risk factors in the 2025 Annual Report.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls deemed effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
-
No material control changes
The company reported no changes during the second quarter of 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
Risk factors unchanged
The company states that risk factors in its 2025 Annual Report remain relevant and that there have been no material changes as of the filing date.
What to watch
-
Legal claim exceeds $3.5 million
The Estate of Christopher Columbus Chapman, Jr. filed a complaint on June 5, 2026, claiming damages in excess of $3.5 million related to delayed transfer of restricted common stock. The company considers the claim without merit but intends to defend it vigorously.
-
Controls cannot ensure full prevention
The company cautions that its control systems provide only reasonable, not absolute, assurance and may not prevent all fraud or material error. This limitation applies despite management’s conclusion that controls were effective as of June 30, 2026.
Management's outlook
The filing provides no quantitative revenue or EPS guidance and does not state a change to prior outlook; financial outlook may be addressed in the August 25, 2026 earnings release or call.
Earlier filings 4
10-K · March 17, 2026
Telomir is a preclinical-stage biotech focused on Telomir-1, an oral small molecule that modulates intracellular metal balance. The company reports multiple favorable preclinical findings and GLP toxicology described as…
10-Q · November 10, 2025
Telomir reported no revenue for the quarter and a materially smaller net loss in Q3 2025 of $(1,102,294) versus $(5,990,733) in Q3 2024, producing improved EPS of $(0.03) vs $(0.20). Cash rose to $7,329,298 as of…
10-Q · May 14, 2025
Telomir reported no revenue and a net loss of $2,179,828 in Q1 2025 (EPS $(0.07)), an improvement versus a net loss of $6,254,607 (EPS $(0.23)) in Q1 2024. Cash declined to $402,999 at March 31, 2025 from $1,266,131 at…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.